Arcus Biosciences, Inc. Deferred Offering Costs
Arcus Biosciences, Inc. (RCUS) had Deferred Offering Costs of $3.60 million as of 2018-03-31, per its 10-K filed 2019-03-05.
Discontinued › Balance Sheet › Assets
us-gaap:DeferredOfferingCosts · last filed 2019-03-05
- 2018-03-31: Deferred Offering Costs $3.60M.
- 2017-12-31: Deferred Offering Costs $1.30M.
| Period end | Deferred Offering Costs |
|---|---|
| 2018-03-31 | $3.60M 10-K · filed 2019-03-05 |
| 2017-12-31 | $1.30M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |